Psilocybin-Assisted Therapy for Common Mental Health Disorders and their Comorbid Presentations: A Scoping Review
Nandita Jowaheer
June 15, 2026 preprint DOI: 10.17605/osf.io/rfqxw (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scoping review (protocol) |
|---|---|
| Intervention | Psilocybin-assisted therapy |
| Topics | Psilocybin |
| Key findings | Proposes a scoping review to map research on psilocybin-assisted therapy for depression, anxiety disorders, substance use disorders, and comorbid presentations, summarize reported therapeutic outcomes, and evaluate the methodological quality of the evidence base. No results or conclusions are reported in the abstract. |
Abstract
This project is a scoping review examining the current evidence base for psilocybin-assisted therapy across depression, anxiety disorders, substance use disorders, and their comorbid presentations. The review aims to map the scope of existing research, summarise reported therapeutic outcomes, and evaluate the methodological quality of the evidence base. The full study rationale, objectives, eligibility criteria, search strategy, and planned methods are provided in the attached protocol document.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |